All In Biotech

Drug Trial Radar · NCT04241068

A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (Aducanumab) in Subjects With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

Last checked: Nov 20, 2026Latest source record: Feb 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,696

Actual

Start

Mar 2, 2020

Primary completion

Jul 22, 2024

Study completion Jul 22, 2024

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Jan 27, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to evaluate the safety and tolerability of aducanumab over 100 weeks of treatment after a wash-out period imposed by discontinuation of feeder studies in participants who had previously received aducanumab (i.e. previously treated participants) or who had previously received placebo (i.e. treatment-naïve participants).

Conditions

  • Alzheimer's Disease

Interventions

  • AducanumabDrug

    Administered as specified in the treatment arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Core Treatment Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEsTime frame: From the first dose of study drug to end of follow-up (up to Week 118)
  2. Core Treatment Period: Number of Participants With AEs Leading to Treatment Discontinuation (TD) and Study Withdrawal (SW)Time frame: From the first dose of study drug to end of follow-up (up to Week 118)
  3. Core Treatment Period: Number of Participants With Amyloid-Related Imaging Abnormality-Edema (ARIA-E)Time frame: Up to Week 118
  4. Core Treatment Period: Number of Participants With Amyloid-Related Imaging Abnormality- Hemorrhage or Superficial Siderosis (ARIA-H)Time frame: Up to Week 118
  5. Core Treatment Period: Number of Participants With Positive Antidrug Antibodies (ADAs) in SerumTime frame: Up to Week 102

Locations

297 sites in 20 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Banner Alzheimer's Institute

    Phoenix, Arizona

  • Dignity Health

    Phoenix, Arizona

  • Banner Sun Health Research Institute

    Sun City, Arizona

  • Center for Neurosciences

    Tucson, Arizona

  • Neurology Center of North Orange County

    Fullerton, California

  • UCI MIND

    Irvine, California

  • University of California San Diego Medical Center

    La Jolla, California

  • Senior Clinical Trials, Inc.

    Laguna Hills, California

  • USC Keck School of Medicine

    Los Angeles, California

  • Mary S. Easton Center for Alzheimer's Disease Research, UCLA

    Los Angeles, California

  • Pacific Neuroscience Medical Group

    Oxnard, California

  • Stanford Hospital and Clinics

    Palo Alto, California

  • Anderson Clinical Research

    Redlands, California

  • Pacific Research Network, Inc

    San Diego, California

  • UCSF - Memory and Aging Center

    San Francisco, California

  • Syrentis Clinical Research

    Santa Ana, California

  • California Neuroscience Research Medical Group Inc.

    Sherman Oaks, California

  • University of Colorado Denver

    Aurora, Colorado

  • IMMUNOe International Research Centers

    Centennial, Colorado

  • Yale University

    Fairfield, Connecticut

  • Invicro

    New Haven, Connecticut

  • Yale University School Of Medicine

    New Haven, Connecticut

  • Research Center for Clinical Studies, Inc.

    Norwalk, Connecticut

  • Georgetown University Clinical Research Unit (CRU)

    Washington D.C., District of Columbia

  • JEM Research

    Atlantis, Florida

  • Bradenton Research Center, Inc

    Bradenton, Florida

  • Brain Matters Research

    Delray Beach, Florida

  • Neuropsychiatric Research Center of Southwest Florida

    Fort Myers, Florida

  • Infinity Clinical Research, LLC

    Hollywood, Florida

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida

  • Mayo Clinic in Florida

    Jacksonville, Florida

  • University of Miami

    Miami, Florida

  • Miami Jewish Health System, Inc

    Miami, Florida

  • Renstar Medical Research

    Ocala, Florida

  • Accelerated Enrollment Solutions (AES)

    Orlando, Florida

  • Clinical Neuroscience Solutions, Inc.

    Orlando, Florida

  • Accelerated Enrollment Solutions (AES)

    Orlando, Florida

  • Palm Beach Neurological Center

    Palm Beach Gardens, Florida

  • Quantum Laboratories Inc.

    Pompano Beach, Florida

Showing 40 of 297 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.